Article

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors

2021-12-24

Abstract excerpt

<h4>SUMMARY</h4> Glioblastoma multiforme (GBM) is characterized by aggressive growth and the poorest prognosis of all brain tumor types. Most therapies rarely provide clinically meaningful improvements in outcomes of patients with GBM. Antibody-drug conjugates (ADCs) are emerging chemotherapeutics with stunning success in cancer management. Although promising, clinical studies of three ADCs for treating GBM, incl...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2f8a9961-3788-58ee-bbfe-7ccaa4127ed7
DOI: 10.1101/2021.12.23.474044

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsDOI 10.1101/2021.12.23.474044Read

Antibody-drug conjugates in glioblastoma therapy: the right drugs to the right cells.Semantic proximity Read

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read

<i>In Vivo</i> Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft modelSemantic proximity Read

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and ResistanceSemantic proximity Read

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesSemantic proximity Read

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read

Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?Semantic proximity Read

Peptide-Drug Conjugates as Next-Generation Therapeutics: Exploring the Potential and Clinical ProgressSemantic proximity Read

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escapeSemantic proximity Read

Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.Semantic proximity Read

Antibody-mediated co-delivery of programmable drug combinationsSemantic proximity Read

Expanding Microgel Parameters to Model the Tumor Microenvironment and Examine Temozolomide Resistance in GlioblastomaSemantic proximity Read